Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Poorly Differentiated Neuroendocrine Carcinomas”

42 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 42 results

Large-scale testing (Phase 3)Looking for participantsNCT05058651
What this trial is testing

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Who this might be right for
Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI) 189
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Not applicableUnknownNCT06400654
What this trial is testing

PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC

Who this might be right for
Neuroendocrine Carcinoma
European Institute of Oncology 100
Testing effectiveness (Phase 2)Study completedNCT00654238
What this trial is testing

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

Who this might be right for
Metastatic Differentiated Thyroid CancerMetastatic Poorly Differentiated Thyroid CancerMetastatic Anaplastic Thyroid Cancer+1 more
University of Pennsylvania 59
Early research (Phase 1)Ended earlyNCT01769222
What this trial is testing

Ipilimumab and Local Radiation for Selected Solid Tumors

Who this might be right for
Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+31 more
Stanford University 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT03728361
What this trial is testing

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Who this might be right for
Grade I Neuroendocrine CarcinomaGrade II Neuroendocrine CarcinomaGrade III Neuroendocrine Carcinoma+9 more
Dwight Owen 55
Not applicableUnknownNCT03896958
What this trial is testing

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

Who this might be right for
Cancer, All TypesCancer of LiverCancer of Stomach+42 more
SpeciCare 1,000
Testing effectiveness (Phase 2)Ended earlyNCT01215578
What this trial is testing

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

Who this might be right for
Neuroendocrine TumorsPancreatic NeoplasmsAdvanced Disease+1 more
Assistance Publique - Hôpitaux de Paris 33
Not applicableStudy completedNCT00899496
What this trial is testing

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

Who this might be right for
Cancer
Wake Forest University Health Sciences 54
Early research (Phase 1)Study completedNCT00049023
What this trial is testing

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsGastrointestinal Carcinoid TumorIslet Cell Tumor+4 more
O'Dorisio, M S 27
Testing effectiveness (Phase 2)Study completedNCT01480986
What this trial is testing

IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC

Who this might be right for
Progression Free Survival of the Treatment
Peking University 40
Early research (Phase 1)Study completedNCT00049296
What this trial is testing

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Who this might be right for
Cancer
Case Comprehensive Cancer Center 26
Early research (Phase 1)Study completedNCT00006368
What this trial is testing

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more
Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04759911
What this trial is testing

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Who this might be right for
Malignant Thyroid Gland NeoplasmPoorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland Carcinoma+4 more
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT03278405
What this trial is testing

Avelumab in G3 NEC

Who this might be right for
Neuroendocrine Carcinoma
Sunnybrook Health Sciences Centre 10
Testing effectiveness (Phase 2)Study completedNCT03591731
What this trial is testing

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Who this might be right for
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique 185
Testing effectiveness (Phase 2)Study completedNCT02113800
What this trial is testing

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Who this might be right for
Poorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 3Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3+2 more
AIO-Studien-gGmbH
Early research (Phase 1)Looking for participantsNCT06889493
What this trial is testing

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

Who this might be right for
Neuroendocrine CarcinomaNeuroendocrine Tumors
Peter Hosein, MD 36
Load More Results
116
40